NBL1 Reduces Corneal Fibrosis and Scar Formation after Wounding

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Cell Biology

Background:

• Corneal scarring is a primary cause of blindness globally.
• Current treatments lack efficacy in preventing or reducing pathological corneal scar formation.
• NBL1 (DAN Family BMP Antagonist) protein expression increases in corneal stromal cells after injury.

Purpose of the Study:

• To investigate the function of NBL1 in corneal wound healing and scar formation.
• To evaluate the anti-fibrotic potential of NBL1 in both murine and human corneal models.
• To elucidate the molecular pathways affected by NBL1 treatment in corneal fibrosis.

Main Methods:

• Mechanical corneal wounding in mice followed by NBL1 treatment.
• Assessment of wound re-epithelialization, stromal thickness, and scar formation.
• Induction of myofibroblasts in cultured human corneas with TGF-β1 and subsequent NBL1 treatment.
• Analysis of BMP canonical (phospho-Smad1/5) and non-canonical (phospho-p38) pathways.

Main Results:

• NBL1 treatment accelerated wound re-epithelialization and partially restored stromal thickness in mice.
• Significant reduction in corneal scar formation was observed in NBL1-treated mice.
• NBL1 treatment decreased myofibroblast formation in human corneas, indicating an anti-fibrotic effect.
• NBL1 inhibited both BMP canonical (Smad1/5) and non-canonical (p38) pathways in human corneal models.

Conclusions:

• NBL1 demonstrates significant potential in reducing corneal fibrosis and scar formation.
• The anti-scarring effect of NBL1 is independent of immune suppression.
• NBL1's mechanism involves the inhibition of both Smad1/5 and p38 pathways, requiring further investigation to determine pathway dominance.